Navigation Links
Defending against chemical acts of terrorism
Date:4/20/2012

ions into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related biology technology :

1. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
2. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
4. MU researchers identify key plant immune response in fight against bacteria
5. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
6. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
8. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
9. Kelly Price Joins Los Angeles County Affiliate of Susan G. Komen for the Cure in the Fight Against Breast Cancer
10. World Hepatitis Alliance Warns that Stigma is a Major Threat to New Initiative Against Hepatitis Epidemic
11. Trudeau Institute announces a discovery in the fight against sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC to ... Mutual (FM) 4910 fire propagation and smoke generation criteria ... tools, fume hoods, furniture and cabinetry. These criteria reduce ... used in electronic chip manufacturing. , Flametec ... workability and superior aesthetics. It is available in a ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... 9 Boston Scientific,Corporation (NYSE: BSX ) ... has revised its Rating Outlook on the Company, ... long-term credit rating of,BB+., Fitch said the ... is making toward stabilizing its drug-eluting stent and ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") ... (PNNL), the Harvard School of,Public Health (HSPH), the ... Drug Administration (FDA) presented data generated through the,use ... last week,s,(June 1-5) American Society for Mass Spectrometry,s ...
... Inc. (Nasdaq:,NUVA), a medical device company focused on developing ... today,that Kevin O,Boyle, Executive Vice President and Chief Financial ... Annual Growth Stock,Conference at the Four Season Hotel, Chicago, ... A live Web cast of the presentation will ...
Cached Biology Technology:Boston Scientific Welcomes Revised Outlook From Fitch Ratings 2Boston Scientific Welcomes Revised Outlook From Fitch Ratings 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 2Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 4NuVasive to Present at William Blair 28th Annual Growth Stock Conference 2NuVasive to Present at William Blair 28th Annual Growth Stock Conference 3
(Date:7/30/2014)... published new research from Bjorn Brembs, professor of neurogenetics ... with a proof-of-concept figure allowing readers and reviewers to ... This represents an important leap forward for scientific publishing, ... quality of a scholarly output. , Figure 3 in ... and their code to F1000Research , and the ...
(Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
(Date:7/30/2014)... a paper published online today in the journal ... researchers Evan Kodra and Auroop Ganguly found that while ... variability in temperature extremes. For instance, while each year,s ... averages will also tend to fall within a wider ... are currently being observed. This means that even as ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... 11, 2013 Elsevier, a world-leading provider of scientific, ... launch of Journal of Forensic Radiology and Imaging ... the International Society of Forensic Radiology and Imaging (ISFRI). ... of forensic radiology and imaging, JOFRI aims ...
... Discovery , the flagship journal of the American Association ... American research centres, presents significant results in treating cancer ... This marks the first time that the therapeutic effect ... Barcelona, 11 February 2013. A study led by Dr ...
... By thinking of cells as programmable robots, researchers at Rice ... tiny blood vessels that feed the brain and help people ... Amina Qutub and her colleagues simulate patterns of microvasculature cell ... their lab. Eventually, they want to develop the ability to ...
Cached Biology News:Elsevier announces the launch of a new journal: Journal of Forensic Radiology and Imaging 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 3Rice University lab show how blood vessels regroup after stroke 2Rice University lab show how blood vessels regroup after stroke 3
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Request Info...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: